Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMEDY-BRVO: Ranibizumab biosimilar vs aflibercept for macular edema due to BRVO
jRCTs031240691Recruiting
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial in macular edema and branch retinal vein occlusion (BRVO) comparing Ranibizumab biosimilar with Aflibercept (2 arms). Primary endpoint: Change in best-corrected visual acuity at week 24. Started Jun 2025; status: recruiting.
02
Drugs
ranibizumabaflibercept
03
Conditions
macular edemabranch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on jRCTs031240691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240691.